Brean Capital Raises PT on Jazz Pharma (JAZZ) to $93

June 21, 2013 11:54 AM EDT
Get Alerts JAZZ Hot Sheet
Price: $150.70 -0.86%

Rating Summary:
    25 Buy, 6 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 26 | Down: 54 | New: 6
Trade JAZZ Now!
Join SI Premium – FREE
Brean Capital maintained a Buy rating on Jazz Pharmaceuticals (NASDAQ: JAZZ) and raised its price target to $93.00 (from $88.00). Analyst Gene Mack said a recent update from management increased his confidence.

"We are increasing our revenue and EPS estimates for FY13 to $870M from $823M and $6.25 from $5.87. The increase represents the high end of FY13 EPS guidance range of $6.10-6.30 and comes mainly from increasing our Erwinaze estimate from $200M to $225M," said Mack.

For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.

Shares of Jazz Pharmaceuticals closed at $65.51 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Add Your Comment